Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indapamide

FDA-approved product (tablet, oral), marketed as Indapamide, Lozol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Indapamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Hypertension
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indapamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indapamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population

    NCT07652567 · start 2007-01-01

    Registered record
    Registry ID
    NCT07652567
    Conditions
    High-normal Blood Pressure
    Interventions
    Telmisartan; Indapamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-01-01
    Completion
    2026-04-30
    Enrolment
    690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-normal Blood Pressure
    InterventionTelmisartan; Indapamide; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

    NCT00128518 · start 2004-10

    Registered record
    Registry ID
    NCT00128518
    Conditions
    Hypertension
    Interventions
    Indapamide (T2); Perindopril (T1); Placebo of Perindopril (P1); Placebo of Indapamide (P2)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-10
    Completion
    2010-09
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIndapamide (T2); Perindopril (T1); Placebo of Perindopril (P1); Placebo of Indapamide (P2)
    PhasePhase 4
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

    NCT00145925 · start 2001-06

    Registered record
    Registry ID
    NCT00145925
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Perindopril-indapamide; Gliclazide MR-based glucose lowering
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    2008-03
    Enrolment
    11,140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPerindopril-indapamide; Gliclazide MR-based glucose lowering
    PhasePhase 3
    Registry statusCompleted

  • Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

    NCT00295542 · start 2000-03

    Registered record
    Registry ID
    NCT00295542
    Conditions
    Hypertension
    Interventions
    Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-04
    Enrolment
    3,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 more
    PhasePhase 4
    Registry statusCompleted